EntryPoint Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
Other funds holding BMY
EntryPoint Capital's BMY Position: Q2 2026 in Review
EntryPoint Capital reduced its Bristol-Myers Squibb (BMY) stake by 83% in Q2 2026, selling an estimated $1.01M and leaving 3,499 shares worth $202K. The position accounts for 0.05% of the portfolio, ranked #695.
EntryPoint Capital first reported a position in BMY in Q4 2023 and has held it in 5 quarters since. The position peaked at $1.27M in Q1 2026. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- EntryPoint Capital held 3,499 shares of Bristol-Myers Squibb worth $202K as of Q2 2026.
- EntryPoint Capital sold 17,511 Bristol-Myers Squibb shares in Q2 2026, an estimated $1.01M.
- Bristol-Myers Squibb made up 0.05% of EntryPoint Capital's portfolio in Q2 2026, its #695 holding.
- EntryPoint Capital first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 5 quarters since.
- EntryPoint Capital's Bristol-Myers Squibb position peaked at $1.27M in Q1 2026.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.